FY2027 EPS Estimates for Surmodics Decreased by Analyst

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Research analysts at Zacks Research reduced their FY2027 earnings per share estimates for shares of Surmodics in a report released on Thursday, March 20th. Zacks Research analyst D. Dey now anticipates that the company will post earnings per share of $0.83 for the year, down from their prior forecast of $0.84. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share.

A number of other equities analysts have also recently commented on SRDX. StockNews.com initiated coverage on Surmodics in a report on Monday, February 3rd. They issued a "hold" rating on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a research report on Thursday, January 30th. Finally, Lake Street Capital raised shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price for the company in a report on Friday, March 7th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Surmodics has a consensus rating of "Hold" and a consensus target price of $50.00.

Surmodics Stock Performance

SRDX traded up $0.13 during trading on Monday, hitting $30.61. The company's stock had a trading volume of 32,528 shares, compared to its average volume of 275,802. The business's 50 day simple moving average is $33.11 and its 200-day simple moving average is $36.87. The firm has a market cap of $437.60 million, a PE ratio of -30.31 and a beta of 1.19. Surmodics has a one year low of $25.17 and a one year high of $42.44. The company has a quick ratio of 4.29, a current ratio of 5.45 and a debt-to-equity ratio of 0.26.

Remove Ads

Surmodics (NASDAQ:SRDX - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

Institutional Trading of Surmodics

Institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System boosted its stake in Surmodics by 5,005.0% in the 4th quarter. California State Teachers Retirement System now owns 50,999 shares of the company's stock worth $2,020,000 after purchasing an additional 50,000 shares during the period. Phocas Financial Corp. boosted its position in shares of Surmodics by 17.6% during the fourth quarter. Phocas Financial Corp. now owns 103,994 shares of the company's stock worth $4,118,000 after acquiring an additional 15,534 shares during the last quarter. Alpine Global Management LLC purchased a new position in Surmodics during the fourth quarter valued at $1,980,000. Squarepoint Ops LLC increased its holdings in Surmodics by 154.9% in the 4th quarter. Squarepoint Ops LLC now owns 162,066 shares of the company's stock valued at $6,418,000 after acquiring an additional 98,489 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in Surmodics by 0.4% in the 4th quarter. Millennium Management LLC now owns 120,344 shares of the company's stock worth $4,766,000 after purchasing an additional 509 shares in the last quarter. Hedge funds and other institutional investors own 96.63% of the company's stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).